Paromomycin sulfate
From Wikipedia, the free encyclopedia
Paromomycin sulfate
|
|
Systematic (IUPAC) name | |
(2R,3S,4R,5R,6S)-5-amino-6-[(1R,2S,3S,4R,6S)- 4,6-diamino-2-[(2S,3R,4R,5R)-4-[(2R,3R,4R,5R,6S)- 3-amino-6-(aminomethyl)-4,5-dihydroxy-oxan-2-yl] oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy- 3-hydroxy-cyclohexyl]oxy-2-(hydroxymethyl)oxane-3,4-diol |
|
Identifiers | |
CAS number | |
ATC code | A07 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C23H47N5O18S |
Mol. mass | 615.629 g/mol |
Pharmacokinetic data | |
Bioavailability | None |
Metabolism | None |
Half life | ? |
Excretion | Fecal |
Therapeutic considerations | |
Pregnancy cat. |
C(US) |
Legal status |
Rx only U.S. |
Routes | Oral, intramuscular |
Paromomycin sulfate (brand name Humatin) is a drug that fights intestinal infections such as cryptosporidiosis and amoeba infection, or amoebiasis and was developed as a therapeutic against visceral leishmaniasis by the Institute for OneWorld Health. Paromomycin was granted orphan drug status in 2005[1] and was approved by the Drug Controller General of India in September 2006 for treatment of visceral leishmaniasis.[2]
Paromomycin inhibits protein synthesis by binding to 16S ribosomal RNA.[3]
As of February 5th, 2008, King Pharmaceuticals is discontinuing the sale of Humatin, Paromomycin continues to be available in the United States from another manufacturer. [1]
[edit] References
- ^ Institute for OneWorld Health (23 May 2005). "Institute for OneWorld Health Drug Receives “Orphan” Designation From U.S. and European Regulatory Agencies". Press release. Retrieved on 2007-02-10.
- ^ Institute for OneWorld Health (8 September 2006). "New cure for deadly visceral leishmaniasis (kala-azar) approved by government of India". Press release. Retrieved on 2007-02-10.
- ^ Vicens, Quentin; Eric Westhof (August 2001). "Crystal Structure of Paromomycin Docked into the Eubacterial Ribosomal Decoding A Site". Structure 9 (8): 647–658. doi: . PMID 11587639.
|